E
Elliott M. Antman
Researcher at Brigham and Women's Hospital
Publications - 738
Citations - 187175
Elliott M. Antman is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 161, co-authored 716 publications receiving 179462 citations. Previous affiliations of Elliott M. Antman include Duke University & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Diltiazem Treatment for Pre-Clinical Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers : A Pilot Randomized Trial to Modify Disease Expression
Carolyn Y. Ho,Neal K. Lakdawala,Allison L. Cirino,Steven E. Lipshultz,Elizabeth Sparks,Siddique Abbasi,Raymond Y. Kwong,Elliott M. Antman,Christopher Semsarian,Arantxa González,Begoña López,Javier Díez,E. John Orav,Steven D. Colan,Christine E. Seidman +14 more
TL;DR: Pre-clinical administration of diltiazem is safe and may improve early LV remodeling in HCM, and this novel strategy merits further exploration.
Journal ArticleDOI
Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13307 patients in five TIMI trials
C. Michael Gibson,Raphaelle Dumaine,Eli V. Gelfand,Sabina A. Murphy,David A. Morrow,Stephen D. Wiviott,Robert P. Giugliano,Christopher P. Cannon,Elliott M. Antman,Eugene Braunwald +9 more
TL;DR: In the setting of NSTE-ACS, impaired GFR is associated with higher mortality as well as higher rates of thrombotic and major bleeding events, independent of TRS.
Journal ArticleDOI
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial
Sabina A. Murphy,Elliott M. Antman,Stephen D. Wiviott,Govinda Weerakkody,Giorgio Morocutti,Kurt Huber,Jose Lopez-Sendon,Carolyn H. McCabe,Eugene Braunwald +8 more
TL;DR: Prasugrel, a more potent anti-platelet agent, reduced both first and subsequent cardiovascular events compared with clopidogrel in patients with ACS.
Journal ArticleDOI
Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial
Marc S. Sabatine,Elliott M. Antman,Petr Widimsky,Iftikhar O Ebrahim,Róbert Gábor Kiss,André Saaiman,Rostislav Polasek,Charles F. Contant,Carolyn H. McCabe,Eugene Braunwald +9 more
TL;DR: In patients with non-ST-elevation acute coronary syndromes, otamixaban infusions of 0.100-0.140 mg/kg/h might reduce ischaemic events and have a safety profile similar to unfractionated heparin plus eptifibatide.
Journal ArticleDOI
Time Is Muscle: Translation Into Practice
TL;DR: Improvements in access to timely care for patients with STEMI will require a multifaceted approach involving patient education, improvements in the Emergency Medical Services and emergency department components of care, as well as coordinated advocacy efforts to work with payers and policy makers to implement a much-needed health care system redesign.